research use only
Cat.No.S2235
| Related Targets | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase |
|---|---|
| Other PLK Inhibitors | BI 2536 Rigosertib Sodium (ON-01910) GSK461364 Onvansertib (NMS-1286937, NMS-P937) CFI-400945 Ro3280 HMN-214 SBE 13 HCl MLN0905 Centrinone (LCR-263) |
|
In vitro |
DMSO
: 35 mg/mL
(56.56 mM)
Water : Insoluble Ethanol : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about Volasertib (BI6727) solubility in DMSO or water
Read more about Volasertib (BI6727) working concentrations for cell culture treatment
| Information | Volasertib (BI6727) is a potent, highly specific, ATP-competitive PLK1 inhibitor. It affects PI3K/AKT/mTOR and AURKA-PLK1-FOXM1 signaling pathways by inducing G2/M cell cycle arrest, promoting DNA damage, and downregulating MYC, effectively inhibiting tumor cell proliferation and promoting apoptosis. |
|---|---|
|
Read more about Volasertib (BI6727) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
| Molecular Weight | 618.81 | Formula | C34H50N8O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 755038-65-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | BI 6727 | Smiles | CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C | ||
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
I wonder how to reconstitute it for in vivo studies?
Answer:
It can be dissolved in 4% DMSO+Corn oil at 2mg/ml for i.p. injection in mice. For oral administration, this compound can be formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl, or suspended in 0.5% Natrosol 250 hydroxyethyl-cellulose as indicated in the publications. We also suggest the vehicle 30% PEG400/0.5% Tween80/5% propylene glycol for a suspension which we tested in house.